Self-inactivating, all-in-one AAV vectors for precision Cas9 genome editing via homology-directed repair in vivo
dc.contributor.author | Ibraheim, Raed | |
dc.contributor.author | Tai, Phillip W L | |
dc.contributor.author | Mir, Aamir | |
dc.contributor.author | Javeed, Nida | |
dc.contributor.author | Wang, Jiaming | |
dc.contributor.author | Rodríguez, Tomás C | |
dc.contributor.author | Namkung, Suk | |
dc.contributor.author | Nelson, Samantha | |
dc.contributor.author | Khokhar, Eraj Shafiq | |
dc.contributor.author | Mintzer, Esther | |
dc.contributor.author | Maitland, Stacy | |
dc.contributor.author | Chen, Zexiang | |
dc.contributor.author | Cao, Yueying | |
dc.contributor.author | Tsagkaraki, Emmanouela | |
dc.contributor.author | Wolfe, Scot A | |
dc.contributor.author | Wang, Dan | |
dc.contributor.author | Pai, Athma A | |
dc.contributor.author | Xue, Wen | |
dc.contributor.author | Gao, Guangping | |
dc.contributor.author | Sontheimer, Erik J | |
dc.date.accessioned | 2023-03-24T13:22:41Z | |
dc.date.available | 2023-03-24T13:22:41Z | |
dc.date.issued | 2021-11-01 | |
dc.identifier.citation | Ibraheim R, Tai PWL, Mir A, Javeed N, Wang J, Rodríguez TC, Namkung S, Nelson S, Khokhar ES, Mintzer E, Maitland S, Chen Z, Cao Y, Tsagkaraki E, Wolfe SA, Wang D, Pai AA, Xue W, Gao G, Sontheimer EJ. Self-inactivating, all-in-one AAV vectors for precision Cas9 genome editing via homology-directed repair in vivo. Nat Commun. 2021 Nov 1;12(1):6267. doi: 10.1038/s41467-021-26518-y. PMID: 34725353; PMCID: PMC8560862. | en_US |
dc.identifier.eissn | 2041-1723 | |
dc.identifier.doi | 10.1038/s41467-021-26518-y | en_US |
dc.identifier.pmid | 34725353 | |
dc.identifier.uri | http://hdl.handle.net/20.500.14038/51879 | |
dc.description.abstract | Adeno-associated virus (AAV) vectors are important delivery platforms for therapeutic genome editing but are severely constrained by cargo limits. Simultaneous delivery of multiple vectors can limit dose and efficacy and increase safety risks. Here, we describe single-vector, ~4.8-kb AAV platforms that express Nme2Cas9 and either two sgRNAs for segmental deletions, or a single sgRNA with a homology-directed repair (HDR) template. We also use anti-CRISPR proteins to enable production of vectors that self-inactivate via Nme2Cas9 cleavage. We further introduce a nanopore-based sequencing platform that is designed to profile rAAV genomes and serves as a quality control measure for vector homogeneity. We demonstrate that these platforms can effectively treat two disease models [type I hereditary tyrosinemia (HT-I) and mucopolysaccharidosis type I (MPS-I)] in mice by HDR-based correction of the disease allele. These results will enable the engineering of single-vector AAVs that can achieve diverse therapeutic genome editing outcomes. | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | Nature Communications | en_US |
dc.relation.url | https://doi.org/10.1038/s41467-021-26518-y | en_US |
dc.rights | Open Access: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/ licenses/by/4.0/. © The Author(s) 2021; Attribution 4.0 International | en_US |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | CRISPR-Cas9 genome editing | en_US |
dc.subject | Targeted gene repair | en_US |
dc.title | Self-inactivating, all-in-one AAV vectors for precision Cas9 genome editing via homology-directed repair in vivo | en_US |
dc.type | Journal Article | en_US |
dc.source.journaltitle | Nature communications | |
dc.source.volume | 12 | |
dc.source.issue | 1 | |
dc.source.beginpage | 6267 | |
dc.source.endpage | ||
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | England | |
dc.identifier.journal | Nature communications | |
refterms.dateFOA | 2023-03-24T13:22:42Z | |
dc.contributor.department | Horae Gene Therapy Center | en_US |
dc.contributor.department | Li Weibo Institute for Rare Diseases Research | en_US |
dc.contributor.department | Molecular, Cell and Cancer Biology | en_US |
dc.contributor.department | Morningside Graduate School of Biomedical Sciences | en_US |
dc.contributor.department | Program in Molecular Medicine | en_US |
dc.contributor.department | RNA Therapeutics Institute | en_US |